Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 16/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.63 |
| ▸ | OPRL1 | P41146 | 15/20 | 0.63 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10316251 | 0.85 | OPRM1 (0.69) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL2554375 | 0.83 | OPRM1 (0.69) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL12219052 | 0.81 | OPRM1 (0.43) | OPRM1OPRK1OPRL1 | |
| SCHEMBL12219053 | 0.81 | OPRM1 (0.43) | OPRM1OPRK1OPRL1 | |
| SCHEMBL14410177 | 0.81 | OXTR (0.47) | OPRM1OPRK1OPRL1 | |
| SCHEMBL14543172 | 0.80 | OPRM1 (0.71) | OPRM1OPRK1OPRL1 | |
| SCHEMBL11930767 | 0.80 | OPRM1 (0.76) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL9837438 | 0.80 | OPRM1 (0.75) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL28667548 | 0.80 | OPRM1 (0.80) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL13361543 | 0.79 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039460-B2 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headache; compounds based on 6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine or 6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepine | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20080113966-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113966-A1 | Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CCKBR | OPRM1 85/4885OPRK1 73/4885OPRL1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.